Sadly, but not unexpectedly, last week the Court of Appeals for the District of Columbia Circuit denied a petition for rehearing filed be Americans for Safe Access in ASA v. DEA. After more than a decade of legal wrangling with the federal government over the medical efficacy of marijuana and its relative lack of abuse potential, the D.C. Circuit gave great deference to the Drug Enforcement Administration (DEA) position that marijuana has no proven medical value. In doing this, the D.C. Circuit not only ignored voluminous evidence of marijuana’s medical efficacy, but it held the petitioners to a standard above and beyond that advanced by the government itself. Out of thin air, the Court interpreted the phrase “adequate and well-controlled studies” to require FDA-approved Phase II or Phase III studies, rather than the common meaning of the term. A similar such standard as that interjected into the proceedings by the Court at the last possible moment had already been rejected by the same Court and others in the cases of Grinspoon v. DEA, 828 F.2d 881 (1st Cir. 1987) and Doe v. DEA, 484 F.3d 561 (D.C. Cir. 2007).  This, coupled with the failure of the Court even to consider marijuana’s lack of abuse potential, was the basis for ASA’s recent petition for rehearing.

(more…)

I spent the last three years working as an Executive Legislative Assistant to a ranking budget chair in the Washington State Legislature, so it should come as no surprise that a trip to the Nation’s Capitol has always been high on my  bucket list. I was this close to fulfilling my dream in 2008, after scrimping and saving for over two years on a relatively low salary. Unfortunately, prohibition happened.

I became a medical cannabis patient in ‘05 while living in Oregon. At that time, I did not know that I had a rare genetic disorder; only that I had long been suffering from chronic joint and muscle pain, extreme nausea and vomiting, disabling migraines and eventual insomnia. After an honest conversation with my doctor about the handfuls of pills I was taking to mask the symptoms – at the ripe ol’ age of 25, mind you – it was suggested that cannabis might relieve what ailed me. I was honestly taken aback when it worked so well and I was able to wean myself off every single pharmaceutical.

(more…)

Americans for Safe Access (ASA) opened the eyes of this thirty-three year law enforcement veteran. Caught in the whirlpool of drug prohibition policy, prohibitionist law enforcement folks as I once was, forget the importance of maintaining an open mind. Unfortunately, “ group-think” is where most of us tend to feel comfortable.

Until roughly four years ago, I knew virtually nothing of medical marijuana. I must say that I was somewhat skeptical of the claim for its medicinal properties. My knowledge of marijuana originated from two places, my experimentation as a teen in 1975 and from an enforcement perspective throughout my lengthy law enforcement career. Neither provided any meaningful insight to the medicinal properties or benefits of marijuana.

(more…)

The US appellate court in Washington, DC, denied our appeal to reschedule cannabis under federal law today, agreeing with the Drug Enforcement Administration’s (DEA) position that “adequate and well-controlled studies” on the medical efficacy of medical cannabis do not exist. Americans for Safe Access (ASA) strongly disagrees with the court’s opinion. Our briefs referenced two hundred peer-reviewed scientific studies proving the medical value of cannabis.

The Obama Administration keeps changing the definition of medical efficacy.  Politics have trumped medical science on this issue. ASA can point to a research approval process for medical cannabis, controlled by the National Institute on Drug Abuse (NIDA), which is unique, overly rigorous, and hinders meaningful therapeutic research. ASA argued in its appeal brief that the DEA has no “license to apply different criteria to marijuana than to other drugs, ignore critical scientific data, misrepresent social science research, or rely upon unsubstantiated assumptions, as the DEA has done in this case.”

(more…)

This is the time of year when I take some time to reflect over the past twelve months and prepare myself for the opportunities that lay ahead in the New Year.

2012 was bittersweet. On one hand, we moved the fight for safe access to medical cannabis forward – adding two new medical cannabis states, Connecticut and Massachusetts; legislatures in a dozen states considered medical cannabis bills; current medical cannabis states tried to tackle regulation and implementation; new and influential allies joined the fight, like the United Food and Commercial Workers (UFCW) and the Americans Herbal Products association (AHPA); and the election brought with it new allies in the Senate and House.

But nineteen of our brothers and sisters spent their holidays in prison, and a half a dozen more will be joining them in the next few months. Millions of patients are left without access following aggressive raids and landlord threats. US Attorneys seem to be hell bent on destroying access models built by states and cities across the country.

(more…)

As the Executive Director of Americans for Safe Access, it’s my privilege to meet and facilitate the work of medical cannabis advocates throughout the nation. In the week before yesterday’s election, I drove all over Arkansas, visiting counties to drop off signs and connect with activists. This is an amazing movement, made up of compassionate people and patients willing to fight for their health. Last night we learned of many victories for patients who can be helped by cannabis, at both the state and federal levels. Most directly, the voters of Massachusetts overwhelmingly supported a compassionate use law, bringing the total number of medical marijuana states to 18 (plus the District of Columbia)!
(more…)

ASA v DEA plaintiffs (l-r) Michael Krawitz, Bill Britt, and Cathy Jordan receive the Courage Award from ASA.

On Tuesday evening, October 16th, Americans for Safe Access celebrated our 10th anniversary – and patients’ day in court – with an awards dinner honoring the brave warriors for medical cannabis access who have fought for all patients. (more…)

Just hours after the U.S. Court of Appeal for the D.C. Circuit heard oral arguments in the federal landmark case Americans for Safe Access v. Drug Enforcement Administration, the court ordered supplemental briefing on the issue of “standing.” In a rare move for a case that has been covered by the Associated Press, Reuters, CNN, Bloomberg News, Los Angeles Times, San Francisco Chronicle, Huffington Post, and others, the request for additional briefing indicates that the court is taking the issue of medical marijuana very seriously.

(more…)

Shortly after California passed Prop. 215 in 1996, I asked the chief physician at my county clinic for a verbal or written recommendation to use cannabis medicinally. He told me that, while he had no problem with me using cannabis for my conditions, he was afraid to make any kind of recommendation without proper authorization and guidelines. He said as long as cannabis is a Schedule I drug, he could not prescribe it to me.

Over the years living with epilepsy and Post-Polio Syndrome, I have been prescribed and used a myriad of over and under the counter medications for pain, seizures, inflammation, nausea (Marinol), anxiety, insomnia etc. and none of the medications I have taken are as effective, tolerable and free of side-effects (both short term and long term) as cannabis.

After being denied by my doctor, I met with the clinic director who said the same thing as every medical professional and county/state health department representative I communicated with: “As long as cannabis is a schedule I drug, I cannot help you.”
(more…)

Today is the 75th anniversary of marijuana prohibition in the U.S. and, as a society, we’re no better off for it. In fact, many would argue that we’re far worse off with prohibition than if at any point we had developed a sensible public health policy with regard to marijuana use.

The effects of marijuana prohibition have been unmistakable from a law enforcement standpoint — the U.S. imprisons more people for marijuana than any other country. However, the effects on society of criminalizing marijuana for therapeutic use are also significant and undeniable.

Before the Marihuana Tax Act (MTA) was passed in 1937, medical marijuana (also known as cannabis) was commonly sold by pharmaceutical companies like Eli Lilly. However, Harry Anslinger, the country’s first drug czar, made sure that no exception was made for such therapeutic uses.

(more…)